Pressure off Teva's CNS hopes as tardive dyskinesia drug succeeds

Teva's investigational drug SD-809 (deutetrabenazine) has hit its endpoint in moderate to severe tardive dyskinesia patients in a pivotal Phase II/III trial, top-line results show. The drug, which Teva acquired when it bought Auspex Pharmaceuticals earlier this year, is one of the leading candidates in this neurological disease, for which there are currently no approved treatments in the US.